152 related articles for article (PubMed ID: 26253838)
1. Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas.
Shastry AH; Thota B; Srividya MR; Arivazhagan A; Santosh V
Pathol Oncol Res; 2016 Apr; 22(2):287-92. PubMed ID: 26253838
[TBL] [Abstract][Full Text] [Related]
2. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes.
Ladha J; Donakonda S; Agrawal S; Thota B; Srividya MR; Sridevi S; Arivazhagan A; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Kondaiah P; Somasundaram K; Santosh V; Rao SM
Cancer Res; 2010 Aug; 70(16):6437-47. PubMed ID: 20663907
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
Chaurasia A; Park SH; Seo JW; Park CK
J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
[TBL] [Abstract][Full Text] [Related]
5. P53 stratification reveals the prognostic utility of matrix metalloproteinase-9 protein expression in glioblastoma.
Shastry AH; Thota B; Arimappamagan A; Santosh V
Neurol India; 2015; 63(3):399-404. PubMed ID: 26053814
[TBL] [Abstract][Full Text] [Related]
6. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
7. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
9. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker.
Harada K; Kurisu K; Tahara H; Tahara E; Ide T; Tahara E
J Neurosurg; 2000 Oct; 93(4):618-25. PubMed ID: 11014540
[TBL] [Abstract][Full Text] [Related]
11. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Li S; Zhang W; Chen B; Jiang T; Wang Z
Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
[TBL] [Abstract][Full Text] [Related]
13. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
[TBL] [Abstract][Full Text] [Related]
14. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
[TBL] [Abstract][Full Text] [Related]
15. GBM-associated mutations and altered protein expression are more common in young patients.
Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
[TBL] [Abstract][Full Text] [Related]
16. MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
Kuan CT; Wakiya K; Herndon JE; Lipp ES; Pegram CN; Riggins GJ; Rasheed A; Szafranski SE; McLendon RE; Wikstrand CJ; Bigner DD
BMC Cancer; 2010 Sep; 10():468. PubMed ID: 20809959
[TBL] [Abstract][Full Text] [Related]
17. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD
Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.
Korshunov A; Golanov A; Sycheva R; Pronin I
J Clin Pathol; 1999 Aug; 52(8):574-80. PubMed ID: 10645226
[TBL] [Abstract][Full Text] [Related]
20. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
Haapasalo JA; Nordfors KM; Hilvo M; Rantala IJ; Soini Y; Parkkila AK; Pastoreková S; Pastorek J; Parkkila SM; Haapasalo HK
Clin Cancer Res; 2006 Jan; 12(2):473-7. PubMed ID: 16428489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
